Search the Newsreel

DexCom earnings on deck: Margin gains in focus amid sensor shift By Investing.com

DexCom (DXCM) is set to report its second-quarter earnings, with analysts focusing on margin expansion as the company transitions customers to its new G7 15-day sensor. Investors will also be watching the pace of G6 to G7 conversions and updates on Medicare coverage expansion …

Dexcom Inc (DXCM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Dexcom Inc (DXCM) as of July 29, 2026, by TradingKey. Dexcom's current valuation score is 7.51, ranking it 154th in the Healthcare Equipment & Supplies industry. The report highlights the company's P/E ratio of 31.42, noting its …

DexCom (DXCM) Q2 Earnings and Revenues Top Estimates

Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Dexcom Inc (DXCM), noting its current risk score of 6.55 within the Healthcare Equipment & Supplies industry. It details the company's beta value of 1.44, indicating higher volatility compared to the S&P 500. The report also includes …

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. The firm encourages current long-term shareholders to contact them to discuss potential corporate governance reforms, the return of funds …

DexCom (DXCM) Could Be 12% Undervalued Following Its Rebound

DexCom (DXCM) stock has seen a recent rebound, with its share price closing at $74.85, prompting investors to assess its current fundamentals and performance. Simply Wall St's analysis suggests the company could be 12.2% undervalued, with a fair value estimate of $85.24, largely due …

DXCM|Dexcom Inc|Price:74.830|Chg%:+1.460

This article provides a detailed analysis of Dexcom Inc. (DXCM) stock, including real-time quotes, key financial figures, and market insights. It highlights the company's strong fundamentals and growth potential, fair valuation, and high institutional ownership, with analysts recommending a "Buy" rating and an expected …

DexCom Earnings: What To Look For From DXCM

DexCom (DXCM) is set to report its Q2 earnings this Thursday, with analysts expecting an 11.5% year-on-year revenue growth. The company has a history of beating revenue expectations, and analysts have largely maintained their estimates. Peer performance from Intuitive Surgical and Abbott Laboratories offers …

DexCom Inc. stock underperforms Tuesday when compared to competitors despite daily gains

DexCom Inc. (DXCM) shares increased by 2.02% on Tuesday, closing at $74.85, even though the broader stock market, represented by the S&P 500 Index and the Dow Jones Industrial Average, also saw gains. This marks the stock's third consecutive day of increases. Despite its …

UBS Adjusts Price Target on DexCom to $96 From $95, Maintains Buy Rating

UBS has raised its price target for DexCom (DXCM) to $96 from $95, while reiterating a Buy rating on the stock. This adjustment comes amidst other recent analyst updates for the medical device company, which specializes in continuous glucose monitoring systems. DexCom recently received …

Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Dexcom Inc (DXCM), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. As of the analysis, DXCM's price momentum score is 3.60, and it is trading within a range suitable for …

Dexcom Inc (DXCM) Institutional Confidence

This article analyzes Dexcom Inc.'s institutional confidence, highlighting its strong ranking within the Healthcare Equipment & Supplies industry. It details the latest institutional shareholding proportion and lists major institutional shareholders and their recent activity. Dexcom Inc (DXCM) has an institutional shareholding score of 10.00, …

DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion

DexCom, Inc. (DXCM) is anticipated to report strong second-quarter 2026 results, driven by robust demand for its G7 continuous glucose monitoring (CGM) systems and expanded reimbursement coverage, particularly for non-insulin type 2 diabetes patients. The company's U.S. and international operations are expected to show …

Dexcom Inc (DXCM) Cash Flow

This article provides a detailed cash flow statement for Dexcom Inc (DXCM), covering quarterly and annual data for operating, investing, and financing activities. It allows users to assess the company's financial health and stability over time. The document also includes definitions and explanations of …

Dexcom stock trades near 52-week high as continuous glucose monitoring growth supports valuation

Dexcom stock is trading near its 52-week high due to strong double-digit revenue growth in its continuous glucose monitoring business and expanding margins. The company reported full-year 2023 revenue of $3.43 billion, up 24%, and Q1 2024 revenue of $921 million, up 25%. This …

Dexcom Inc (DXCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Dexcom Inc (DXCM), categorizing its income by business segments and regional contributions. The data shows that the Distributor segment accounts for the vast majority of revenue, while the United States is the primary regional market. Financial …

Dexcom Inc (DXCM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the major shareholders and institutional holdings of Dexcom Inc (DXCM). It lists the top individual institutional shareholders like Vanguard Capital Management and BlackRock, along with their respective proportions. The article also breaks down shareholder types and provides a historical overview of …

Dexcom Inc (DXCM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Dexcom Inc's (DXCM) dividend and stock split history. It indicates that Dexcom has not distributed any dividends in the past five years. However, it notes a 1-for-4 stock split that occurred on March 28, 2022.

Dexcom Selected as First Manufacturer in FDA's Innovative Digital Health Outcomes Program

Dexcom has been selected as the first manufacturer to participate in the FDA's Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot. Through its Glucose Health Program, Dexcom will support CMS's ACCESS Model by offering continuous glucose monitoring to improve glycemic control and …

DXCM Stock Price and Chart — NASDAQ:DXCM

This article provides a comprehensive overview of DexCom, Inc. (DXCM) stock, including its current price, key financial data, performance metrics, and analyst ratings. It also features various trading ideas and technical analyses from the TradingView community, discussing potential breakouts, support levels, and both bullish …

Dexcom Inc|Price:71.540|Chg%:+1.060

Dexcom Inc (DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes management, including products like Dexcom G6, G7, and Stelo. The company's primary revenue source is its Distributor business, which generated 3.96B in Q1 2026. Key executives include …

Does DexCom’s (DXCM) Longer-Wear G7 Approval Hint At A Durable Edge In Connected Diabetes Care?

DexCom, Inc. recently received Health Canada approval for its Dexcom G7 15 Day Continuous Glucose Monitoring System, extending wear time and enhancing its competitive position in diabetes care. This approval supports DexCom's strategic focus on expanding beyond Type 1 diabetes patients to the larger …

Dexcom Gets First Slot In FDA-CMS Pilot That Rewards Real-World Data At Scale

Dexcom has been selected as the first participant in the FDA-CMS TEMPO pilot program. This initiative, announced in late 2025, aims to evaluate a new regulatory framework for digital health technologies used in chronic disease management by collecting real-world performance data. This move highlights …

FDA names Dexcom as first participant in digital health pilot

The FDA has selected Dexcom as the inaugural participant in its new Technology-Enabled Meaningful Patient Outcomes (TEMPO) digital health pilot. This initiative will allow Dexcom to bypass certain premarket authorization requirements for selected digital health devices while collecting real-world data through a complementary Medicare …

DexCom (DXCM) Earnings Expected to Grow: Should You Buy?

DexCom Inc. stock outperforms competitors despite losses on the day

Shares of DexCom Inc. (DXCM) experienced a 1.24% decline to $74.75, marking its third consecutive day of losses, despite a positive trading session for the broader market. The S&P 500 Index rose 0.89% and the Dow Jones Industrial Average increased by 0.74%. The article …

Dexcom Inc (DXCM) chair Kevin Sayer sells 26,756 shares under 10b5-1 plan

Dexcom Inc's Executive Chair, Kevin R. Sayer, sold 26,756 shares of common stock on July 20, 2026, at a weighted average price of $76.3193 per share. This sale was conducted under a Rule 10b5-1 trading plan established on February 18, 2026, for the orderly …

Dexcom stock trades near 52-week high as G7 CGM growth supports earnings momentum

Dexcom stock is trading near its 52-week high, driven by strong growth in revenue from its G7 continuous glucose monitoring platform and improved profitability. The company reported double-digit revenue growth in fiscal 2025, reaching $4.0 billion, and anticipates further growth of 15% to 20% …

DexCom Inc. stock underperforms Monday when compared to competitors

DexCom Inc. (DXCM) shares fell 1.25% on Monday, closing at $75.69, underperforming the broader market. This marked the stock's second consecutive day of losses while the S&P 500 and Dow Jones Industrial Average also experienced declines.

Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale

A Dexcom (NASDAQ: DXCM) executive, Kevin R. Sayer, plans to sell 26,756 common shares of the company, valued at approximately $2,041,999.19. These shares originated from performance and restricted stock awarded on March 8, 2021, and the sale will be facilitated by Morgan Stanley Smith …

Enterprise value to EBIT forward of DexCom, Inc. – FWB:DC4

The article references the enterprise value to EBIT forward for DexCom, Inc. (FWB:DC4) on the Frankfurt Stock Exchange. It appears to be a financial data snippet from TradingView, directing users to more detailed financial information and tools for the company.

DXCM5813816 Bond Profile — Key Metrics

This article provides key metrics for the DexCom, Inc. bond DXCM5813816, a 0.375% bond maturing on May 15, 2028. It details the issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. DexCom, Inc. is described as a medical device …

Form 4 DexCom Inc For: 16 July By Investing.com

This article from Investing.com reports on a Form 4 filing for DexCom Inc (DXCM) on July 16th. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be submitted by company insiders, such as officers, directors, or …

Dexcom EVP chief legal compliance off sells $126,514 in stock

Dexcom's EVP and Chief Legal Compliance Officer, Michael Jon Brown, sold 1,700 shares of company stock for $126,514 on July 15, 2026, as part of a pre-arranged trading plan. Despite the sale, Brown still holds over 104,000 shares, including unvested restricted stock units. Dexcom …

DexCom Inc (DXCM) Stock Up 7.2% and Still Undervalued -- GF Scor

DexCom Inc (DXCM) shares rose 7.2% to $77.98, and the stock is considered "Modestly Undervalued" by GuruFocus' GF Value™ with a potential 25.3% upside. The company has a strong GF Score™ of 94/100, particularly excelling in Growth (10/10), despite recent insider selling of $5.2 …

DEXCOM INC (DXCM) EVP reports 1,700-share planned stock sale in Form 4

Dexcom Inc.'s EVP Chief Legal Compliance Officer, Michael Jon Brown, reported a planned open-market sale of 1,700 shares of DXCM common stock on July 15, 2026, at an average price of $74.42 per share. This transaction was executed under a 10b5-1 plan adopted in …